miR-487a-3p upregulated in type 1 diabetes targets CTLA4 and FOXO3

Żurawek, Magdalena; Dzikiewicz‐Krawczyk, Agnieszka; Iżykowska, Katarzyna; Ziółkowska-Suchanek, Iwona; Skowrońska, Bogda; Czainska, Maria; Podralska, Marta; Fichna, Piotr; Przybylski, Grzegorz K.; Fichna, Marta; Nowak, Jerzy

doi:10.1016/j.diabres.2018.05.044

Cited by 33 publications

(22 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression analysis did not display significantly higher miR-652-5p expression level in patients with severe form of T1D compared to control group. The observation stays in opposite to our previous microarray experiment [23]. The discrepancy in expression level between microarray and validation analysis might be partially explained by the relative small sample size of microarray cohort (patients with DKA, n = 7).…”

Section: Discussioncontrasting

confidence: 96%

“…Our previous analysis of miRNA expression profile on Affymetrix miRNA 4.1 array in new onset T1D group indicated overexpression of miR-652-5p in patients presenting severe form of autoimmune disease [23]. We observed statistically significant upregulation of miR-652-5p in patients with initial diabetic ketoacidosis (DKA) compared to healthy controls (p = 0.04, fold change 4.72).…”

Section: Introductionmentioning

confidence: 71%

See 1 more Smart Citation

Overexpression of miR-652-5p in new onset type 1 diabetes

Żurawek

Dzikiewicz‐Krawczyk

Iżykowska

et al. 2018

Clinical Diabetology

Self Cite

View full text Add to dashboard Cite

Introduction. MicroRNAs (miRNAs) are small noncoding RNA regulating gene expression at the posttranscriptional level. miRNAs have emerged as an important regulators of central and peripheral immune tolerance, therefore study the RNA molecules in the context of type 1 diabetes (T1D) pathogenesis is an important issue. The aim of this study was to investigate miR-652-5p expression level in the new onset T1D and an impact on ADAR and MARCH5, potential target genes. Material and methods. The miR-652-5p expression was investigated in the peripheral blood mononuclear cell of newly diagnosed T1D pediatric patients (n = 28) and age-matched controls (n = 28) by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). miRNA targets were analyzed by luciferase reporter assays. Results. Expression analysis revealed upregulation of miR-652-5p in T1D group compared to non-diabetic controls (p < 0.05). Luciferase reporter assay did not indicated ADAR and MARCH5 as miR-652-5p targets. Conclusion. Our study revealed miR-652-5p as potential marker of new onset type 1 diabetes.

show abstract

Section: Discussioncontrasting

confidence: 96%

Section: Introductionmentioning

confidence: 71%

Overexpression of miR-652-5p in new onset type 1 diabetes

Żurawek

Dzikiewicz‐Krawczyk

Iżykowska

et al. 2018

Clinical Diabetology

Self Cite

View full text Add to dashboard Cite

show abstract

“…16,17 Our studies showed that miR-885-3p was down-regulated in PBMCs from T1D patients, which was consistent with recent findings from Zuraek et al. 10 Consistently, our results indicated that miR-885-3p had inhibitory actions on the immune response of THP-1 cells.…”

Section: Discussionsupporting

confidence: 92%

“…13 MiR-885-3p exerted its tumor suppressive effects in colon cancer via the disruption of angiogenesis. 10 Consistently, our results indicated that miR-885-3p had inhibitory actions on the immune response of THP-1 cells. 15 Moreover, miR-885-3p acted as a tumor suppressor in glioblastoma and gastric cancer.…”

Section: Tlr4 Was Directly Targeted By Mir-885-3psupporting

confidence: 83%

See 1 more Smart Citation

MiR‐885‐3p is down‐regulated in peripheral blood mononuclear cells from T1D patients and regulates the inflammatory response via targeting TLR4/NF‐κB signaling

Zhang

Wang

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background: Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the progressive destruction of insulin-production pancreatic β cells. Recently, microRNAs (miRNAs) have emerged as important regulators in T1D. The present study aimed to determine miR-885-3p expression in T1D patients and to examine the effects of miR-885-3p on the inflammatory response in human monocytes.Methods: Relevant gene expression levels were determined by a quantitative polymerase chain reaction; western blotting and enzyme-linked immunosorbent assays determined the respective protein levels; and the interaction between miRNA and the downstream targets was evaluated using a luciferase reporter assay.Results: MiR-885-3p is down-regulated and the levels of pro-inflammatory cytokines are increased in peripheral blood mononuclear cells (PBMCs) from T1D patients compared to healthy controls. MiR-885-3p overexpression suppressed mRNA expression and secreted protein levels of pro-inflammatory cytokines in THP-1. A luciferase reporter assay showed that miR-885-3p directly targeted the 3'untranslated region of Toll-like receptor 4 (TLR4) and miR-885-3p overexpression down-regulated TLR4 expression in THP-1 cells. The TLR4 mRNA expression level was increased in PBMCs isolated from T1D patients compared to heathy controls.TLR4 overexpression increased the secretion of pro-inflammatory cytokines and enhanced the activity of NF-κB signaling, and also attenuated the inhibitory effects of miR-885-3p overexpression on pro-inflammatory cytokine secretion and the activity of NF-κB signaling in THP-1 cells. Conclusions:The present study identified the down-regulation of miR-885-3p and up-regulation of TLR4 in PBMCs isolated from T1D patients. Further mechanistic data demonstrated that miR-885-3p overexpression represses the production of proinflammatory cytokines via targeting TLR4/NF-κB signaling in THP-1 cells.

show abstract

Retraction

Fan¹,

Hao²,

Cen³

et al. 2021

Drug Development Research

View full text Add to dashboard Cite

Retraction: ‘Downregulation of miR‐487a‐3p suppresses the progression of non‐small cell lung cancer via targeting Smad7’ by Fan Y, Hao J, Cen X, Song K, Yang C, Xiao S, Cheng S, Drug Development Research. 2021. https://doi.org/10.1002/ddr.21876. The above article, published online on 15 September 2021 in Wiley Online Library (http://wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor‐in‐Chief, Steven Fletcher, and Wiley Periodicals, LLC. The retraction has been agreed upon due to mycoplasma contamination of the cell lines used in the study which may affect the reliability of the conclusions.

show abstract

miR-487a-3p upregulated in type 1 diabetes targets CTLA4 and FOXO3

Cited by 33 publications

References 42 publications

Overexpression of miR-652-5p in new onset type 1 diabetes

Overexpression of miR-652-5p in new onset type 1 diabetes

MiR‐885‐3p is down‐regulated in peripheral blood mononuclear cells from T1D patients and regulates the inflammatory response via targeting TLR4/NF‐κB signaling

Retraction

Contact Info

Product

Resources

About